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Abstract
MicroRNAs regulate target gene expression
post-transcriptionally in a myriad of cell types and play
critical roles in diverse physiological and pathological
processes, including cardiomyocyte development,
differentiation, and regeneration. The recent
publication in Stem Cell Research and Therapy by Wagh
and colleagues reports a novel regulatory role for
miR-363 in cardiomyocyte specification. By employing
microRNA expression profiling and functional
knockdown studies on human embryonic stem
cell-derived cardiomyocytes, the authors identified
miR-363 as an upstream negative regulator of left
ventricular specification transcription factor HAND1.
The efficient derivation of specialized and functional
cardiomyocytes (CMs) from pluripotent stem cells is a
primary goal for stem cell-based cardiac regenerative
therapies. Such a prospect is currently hampered, how-
ever, in part by an incompletely defined complex of
molecular regulators of cardiac cell development and
differentiation.
This commentary discusses the findings from Wagh
and colleagues published in this issue of Stem Cell
Research and Therapy demonstrating a critical role for
miR-363 in post-transcriptional regulation of CM differ-
entiation via the hand and neural crest derivative
expressed HAND1 transcription factor [1]. Teleost fishes
and amphibians show robust regeneration abilities of
heart tissues, whereas the adult mammalian heart poorly
renews itself, showing extremely limited regenerative
capacity. CM proliferative capacity rapidly ceases shortly
after birth in mammals [2]. There is little evidence for
* Correspondence: manoj.gupta@joslin.harvard.edu
1Section of Islet Cell and Regenerative Biology, Joslin Diabetes Center,
Harvard Medical School, Boston, MA 01125, USA
Full list of author information is available at the end of the article
© Gupta and Rao; licensee BioMed Central Ltd. The licensee has exclusive rights to distribute this article, in any medium,
for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
cardiac cell renewal in humans [3], indicating the limited
proliferation capacity of adult CMs. During myocardium
infarction or heart failure, the extensive loss of CMs
leads to progressive cardiac dysfunction and chronic
heart failure, a leading cause of morbidity and mortality
in the developed world. Identifying molecular regulators
and critical mediators of cardiac cell type development,
proliferation, and differentiation is of great clinical im-
portance, and unraveling such molecular horizons could
lead to the development of therapeutic strategies for suc-
cessful regeneration of the human adult heart.
MicroRNAs (miRNAs) are small noncoding RNAs
(~22 nucleotides in length) that regulate gene expression
post-transcriptionally by imperfect binding to the 3′ un-
translated region of target mRNAs in a wide variety of
cell types. Given the notion that a single miRNA may
have multiple cellular targets and given the existence of
vast numbers of miRNAs (~1,500 in humans), we can
expect to witness the discovery of novel miRNA-
dependent regulation in the modulation of versatile
biological functions [4]. Recently, miRNAs have been
recognized as important players in cardiac development,
pathology, and regeneration. Disruption of the miRNA
pathway in CMs leads to heart failure and cardiomyop-
athy [5]. Some miRNAs have been demonstrated to sup-
press CM proliferation, including miR-1, miR-133, and
the miR-15 family, while other miRNAs (miR-199a and
miR-590) have been shown to promote in vivo CM pro-
liferation in rat and mouse models [6,7]. miRNAs could
thus be the best targets for understanding cardiac
specialization during differentiation of human embry-
onic stem cells (hESCs). Further exploring the role of
miRNAs in cardiac cells during development and disease
may therefore hold great promise for cardiac therapy
applications.
hESCs are a unique source for deriving cardiac cells in
a specialized manner and also offer a unique opportunity
to study the mechanisms and derivation of different
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by Wagh and colleagues sought to identify the novel
miRNAs regulating cardiac-specific transcription factors
that determine left versus right ventricular determin-
ation [1]. To this end, the authors performed miRNA ex-
pression profiling in undifferentiated hESCs and CMs at
day 8 and day 14 after differentiation. This screening
identified 18 differentially expressed candidate miRNAs,
from which they focused on miRNAs that could poten-
tially target the 3′ untranslated regions (as predicted by
in silico analysis) of the CM subtype specification tran-
scription factors (HAND1, HAND2, TBX3, GJA1, NPPA,
RYR2, SLN), and found that a subset of miRNAs (miR-
363, miR-367, miR-181a and miR-181c) was expressed at
a higher level in hESC-derived non-CMs compared with
CMs. These novel findings were confirmed by real-time
polymerase chain reaction analysis: higher expression of
HAND genes correlated with lower expression of miR-
363, miR-367, miR-181a and miR-181c. Using an elegant
dual-reporter assay, the authors further showed that
miR-363 specifically inhibits HAND1 gene expression
through 3′ untranslated region binding. Perhaps more
heartening, overexpression of antisense oligonucleotide
directed against miR-363 (anti-miR-363) during hESC
differentiation promoted more HAND1-expressing CMs,
confirming the role of miR-363 in dorso-ventral pattern-
ing and interventricular septum formation in the embry-
onic heart [10,11] (Figure 1).
In summary, Wagh and colleagues demonstrated for
the first time that miR-363 acts as an upstream negative
regulator of HAND1 transcription factor and extends
the role of miRNAs in cardiac cell biology (Figure 1).
This study has important implications for the human
clinical perspective. For instance, since it is especially of
great interest to derive specific cardiac subtypes from
embryonic stem cell/induced pluripotent stem cell cul-
tures and ventricular heart cells, which are the most af-
fected cells during cardiac injury, the reversible
pharmacological suppression of miR-363 may provide a
novel strategy for generating functional left ventricular
CMs for cardiac regenerative therapy.
Nevertheless, Wagh and colleagues’ study opens new
areas of research and presents several unanswered ques-
tions for future investigations. The current study is
impressive, but does the miR-363-mediated repression of
HAND1 occur in vivo? To what extent does this regula-
tion affect the cardiac cell specification during develop-
ment? Is it safe to use anti-miR-363 for cardiac
regenerative therapies? What are the additional miRNA
networks that cooperate with miR-363 to form a high-
order regulatory complex in determining cardiac cell
specification? Most importantly, how can we derive the
desired functional cardiac subtype without any genetic
manipulation? These are just a few of the myriad ques-
tions that are emerging from this exciting study.
Answering these questions may identify more druggable
targets and might help push cardiac research much
closer to human cardiac regenerative therapy.
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Figure 1 miR-363 negatively regulates the left ventricular cardiomyocyte specification transcription factor HAND1. BMP, bone
morphogenetic protein; HAND, hand and neural crest derivative expressed; miR, microRNA; NKX2.5, NK2 transcription factor related, locus 5.
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